Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 9/20 | 0.40 |
| ▸ | ATXN2 | Q99700 | 9/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 4/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | BTD | P43251 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31464547 | 0.93 | SMYD3 (0.44) | ENPP2ATXN2MGLLFASNPDE4B | |
| SCHEMBL31464602 | 0.88 | PKM (0.48) | MGLLSMYD3JAK2 | |
| SCHEMBL31464514 | 0.87 | MGLL (0.41) | ENPP2ATXN2MGLLFASNPDE4B | |
| SCHEMBL31464563 | 0.84 | SMYD3 (0.41) | ENPP2ATXN2MGLLFASNSMYD3 | |
| SCHEMBL31464356 | 0.83 | HPGD (0.50) | MGLLFASNSMYD3 | |
| SCHEMBL31464401 | 0.82 | FASN (0.46) | MGLLFASNSMYD3SLC22A12 | |
| SCHEMBL31464497 | 0.82 | HPGD (0.52) | MGLLFASNSMYD3 | |
| SCHEMBL31464394 | 0.80 | SMYD3 (0.49) | MGLLSMYD3JAK2 | |
| SCHEMBL31464847 | 0.80 | PIK3CA (0.40) | JAK2 | |
| SCHEMBL31464555 | 0.79 | ALOX5AP (0.46) | MGLLFASNSMYD3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | RIPK3, RIPK1, RIPK2 | ENPP2 759/4885ATXN2 3743/4885MGLL 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.